Detalhe da pesquisa
1.
Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial.
J Am Acad Dermatol
; 90(3): 485-493, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-37852306
2.
Romosozumab Efficacy in Postmenopausal Women With No Prior Fracture Who Fulfill Criteria for Very High Fracture Risk.
Endocr Pract
; 29(9): 716-722, 2023 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-37406858
3.
Consistent Efficacy of Apremilast in Patients with Psoriasis Regardless of Baseline Disease Severity or Special Area Involvement: Subgroup Analysis from PROMINENT.
Dermatol Ther (Heidelb)
; 14(6): 1587-1597, 2024 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-38801606
4.
Effect of Romosozumab Treatment in Postmenopausal Women With Osteoporosis and Knee Osteoarthritis: Results From a Substudy of a Phase 3 Clinical Trial.
ACR Open Rheumatol
; 6(1): 43-51, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-37985218
5.
Closing the gap in osteoporosis management: the critical role of primary care in bone health.
Curr Med Res Opin
; 39(3): 387-398, 2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36597741
6.
Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals.
JBMR Plus
; 5(11): e10546, 2021 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-34761149